Polycythemia Vera Therapeutic and Overview Pipeline Review H2

WiseGuyReports.com adds Exclusive Research on “Polycythemia Vera – Pipeline Review, H1 2016” reports to its database.


The report provides comprehensive information on the therapeutics under development for Polycythemia Vera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polycythemia Vera and features dormant and discontinued projects.


GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/393584-polycythemia-vera-pipeline-review-h1-2016                                      


Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.



– The report provides a snapshot of the global therapeutic landscape of Polycythemia Vera

– The report reviews pipeline therapeutics for Polycythemia Vera by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Polycythemia Vera therapeutics and enlists all their major and minor projects

– The report assesses Polycythemia Vera therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Polycythemia Vera


Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand important and diverse types of therapeutics under development for Polycythemia Vera

– Identify potential new clients or partners in the target demographic

– Develop strategic initiatives by understanding the focus areas of leading companies

– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding Polycythemia Vera pipeline depth and focus of Indication therapeutics

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Table of Content: Key Points


Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Polycythemia Vera Overview 7

Therapeutics Development 8

Pipeline Products for Polycythemia Vera – Overview 8

Polycythemia Vera – Therapeutics under Development by Companies 9

Polycythemia Vera – Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Polycythemia Vera – Products under Development by Companies 13

Polycythemia Vera – Companies Involved in Therapeutics Development 14

Bristol-Myers Squibb Company 14

Galena Biopharma, Inc. 15

Gilead Sciences, Inc. 16

Italfarmaco S.p.A. 17

Karus Therapeutics Limited 18

Merck & Co., Inc. 19

miRagen Therapeutics, Inc. 20

Nerviano Medical Sciences S.r.l. 21

Novartis AG 22

PharmaEssentia Corporation 23

Polycythemia Vera – Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29



ACCESS REPORT @ https://www.wiseguyreports.com/reports/393584-polycythemia-vera-pipeline-review-h1-2016   


Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: https://twitter.com/WiseGuyReports                                                                  

Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Media Contact
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: sales@wiseguyreports.com
Phone: +1 646 845 9349, +44 208 133 9349
City: New York City
State: NY
Country: United States
Website: www.wiseguyreports.com